B-cell malignancies and lymphoid cancers
BeOne Medicines AG focuses extensively on chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, Waldenström’s macroglobulinemia, and broader B-cell malignancies. Its research portfolio also includes mature B-cell malignancies and relapsed or refractory disease across these hematologic cancers.
- CLL/SLL
- Mantle cell lymphoma
- Follicular lymphoma and marginal zone lymphoma
- Waldenström’s macroglobulinemia
The company’s clinical work in this area spans both previously untreated and relapsed or refractory settings, with a strong emphasis on lymphoid malignancies.
Myeloid malignancies and multiple myeloma
The sponsor is active in acute myeloid leukemia, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, and relapsed or refractory multiple myeloma. Its research also covers myeloid malignancies more broadly, including advanced hematologic disease requiring targeted therapeutic strategies.
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Myelodysplastic/myeloproliferative neoplasms
- Multiple myeloma
Its clinical research in hematology extends across disease subsets with high unmet need, including refractory and previously treated populations.
Solid tumors and tumor genomics
BeOne Medicines AG also funds studies in advanced or metastatic solid tumors, including non-small cell lung cancer, metastatic gastric or gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma, and HR+/HER2- breast cancer. Genomically defined populations are a major theme, with research in KRAS-mutated tumors, EGFR-mutant non-small cell lung cancer, and MTAP-deleted solid tumors.
- Non-small cell lung cancer
- Head and neck squamous cell carcinoma
- Gastric and gastroesophageal junction adenocarcinoma
- KRAS– and EGFR-driven solid tumors
These programs reflect a broad interest in targeted treatment development for molecularly selected advanced cancers.
Immune-mediated and renal disease
Beyond oncology, the sponsor is involved in primary membranous nephropathy, indicating interest in immune-mediated kidney disease and related therapeutic approaches. This area adds a non-malignant dimension to its clinical portfolio.
- Primary membranous nephropathy
- Renal immunology
The presence of this program shows engagement with autoimmune and inflammatory disease biology alongside its cancer-focused research.
Targeted therapies and immuno-oncology
The clinical portfolio includes studies of BCL2 inhibition, BTK-directed therapy, KRAS inhibition, PRMT5 inhibition, and CDK4 inhibition, together with PD-1/immunotherapy-based approaches such as tislelizumab. Combination strategies are explored across hematologic malignancies and solid tumors.
- BCL2 and BTK-targeted therapy
- KRAS, PRMT5, and CDK4 inhibition
- Tislelizumab
- Combination immuno-oncology
These research areas connect hematology, solid tumor oncology, and molecularly targeted drug development within the sponsor’s clinical program.
